Cargando…
Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds
OBJECTIVES/HYPOTHESIS: Dupilumab, a fully human monoclonal antibody that blocks the shared interleukin (IL)‐4/IL‐13 receptor component, significantly improved outcomes for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in the SINUS‐24 and SINUS‐52 studies. This post hoc analysis eva...
Autores principales: | Chuang, Chien‐Chia, Guillemin, Isabelle, Bachert, Claus, Lee, Stella E., Hellings, Peter W., Fokkens, Wytske J., Duverger, Nicolas, Fan, Chunpeng, Daizadeh, Nadia, Amin, Nikhil, Mannent, Leda P., Khan, Asif H., Kamat, Siddhesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299704/ https://www.ncbi.nlm.nih.gov/pubmed/34817082 http://dx.doi.org/10.1002/lary.29911 |
Ejemplares similares
-
Clinical characteristics of patients with CRSwNP with intensely high eosinophil level
por: Ma, Ling, et al.
Publicado: (2022) -
Differences in men and women suffering from CRSwNP and AERD in quality of life
por: Bartosik, Tina J., et al.
Publicado: (2020) -
Calprotectin in nasal secretion: a new biomarker of non-type 2 inflammation in CRSwNP
por: De Corso, Eugenio, et al.
Publicado: (2022) -
EUFOREA consensus on biologics for CRSwNP with or without asthma
por: Fokkens, Wytske J., et al.
Publicado: (2019) -
Rapid and Continuing Improvements in Nasal Symptoms with Dupilumab in Patients with Severe CRSwNP
por: Bachert, Claus, et al.
Publicado: (2022)